Literature DB >> 1992635

Prognostic factors in alcoholic liver disease. VA Cooperative Study Group.

A Chedid1, C L Mendenhall, P Gartside, S W French, T Chen, L Rabin.   

Abstract

Two hundred eighty-one alcoholic patients were prospectively evaluated by clinical, biochemical, and histologic parameters during a 4-yr period to assess their prognosis. They were stratified into four categories of injury: 1) fatty liver (26 patients), 2) acute alcoholic hepatitis (106), 3) cirrhosis (39), and 4) cirrhosis with superimposed alcoholic hepatitis (111). The rate of survival and variables correlating with survival varied according to the group. At 48 months, 70% of the patients with fatty liver were alive, 58% in the alcoholic hepatitis group, 49% in cirrhosis, and 35% in alcoholic hepatitis superimposed upon cirrhosis. Within group one, deaths were due to causes unrelated to liver disease. In the alcoholic hepatitis group, factors significantly correlating with survival were ascites, alanine amino-transferase levels, grams of alcohol consumed, continuation of alcohol intake, and clinical severity of disease. Survival in patients of group three correlated significantly with prothrombin time and histologic severity score. Patients with combined cirrhosis and alcoholic hepatitis exhibited the worst prognosis, with the most significant predictors of survival being age, grams of alcohol consumed, the ratio of serum aminotransferases (AST:ALT) and the histologic and clinical severity of the disease. Although a different pattern of correlates was observed for each pathologic level of injury, knowledge of the various correlates aids in prognostic assessment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992635

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  45 in total

1.  Alcoholic Liver Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

2.  Predicting utility of a model for end stage liver disease in alcoholic liver disease.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Larissa Vasilieva; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

3.  M-30 and 4HNE are sequestered in different aggresomes in the same hepatocytes.

Authors:  Fataneh Amidi; Barbara A French; David Chung; Charles H Halsted; Valentina Medici; Samuel W French
Journal:  Exp Mol Pathol       Date:  2007-10-25       Impact factor: 3.362

Review 4.  Implication of altered proteasome function in alcoholic liver injury.

Authors:  Natalia A Osna; Terrence-M Donohue
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

5.  TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration.

Authors:  Yoon Seok Roh; Bi Zhang; Rohit Loomba; Ekihiro Seki
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-04-30       Impact factor: 4.052

6.  Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes.

Authors:  Patricia P Bloom; Amirkasra Mojtahed; Emily D Bethea; Sally A Knooihuizen; Jin Choi; Jules L Dienstag; Raymond T Chung; Chin Hur
Journal:  Dig Dis Sci       Date:  2019-07-30       Impact factor: 3.199

7.  Alcoholic Hepatitis.

Authors:  Kester I. Crosse; Frank A. Anania
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

8.  Alcoholic liver disease - Hepatocellular carcinoma transformation.

Authors:  Samuel W French; James Lee; Jim Zhong; Timothy R Morgan; Virgil Buslon; William Lungo; Barbara A French
Journal:  J Gastrointest Oncol       Date:  2012-09

9.  Changes in mitochondrial DNA and its encoded products in alcoholic cirrhosis.

Authors:  Chun Tang; Xianchun Liang; Hongming Liu; Liping Guo; Ruxian Pi; Juntao Yang
Journal:  Int J Clin Exp Med       Date:  2012-06-15

10.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.